for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Health

Roche, Blueprint lung cancer drug wins FDA approval

FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland January 30, 2020. REUTERS/Arnd Wiegmann/File Photo

(Reuters) - Roche Holding AG on Friday said a therapy it co-developed with Cambridge-based Blueprint Medicines Corp was approved by the U.S. health regulator for the treatment of patients with a type of non-small cell lung cancer (NSCLC).

The drug, Gavreto, is an oral therapy which selectively targets so-called RET-altered cancers that have mutations that drive tumor growth, which are detected by a test approved by the U.S. Food and Drug Administration.

Swiss drugmaker Roche in July struck a pact worth up to $1.7 billion with Blueprint Medicines, for rights to Gavreto, which also awaits FDA approval for treating advanced RET mutant and RET fusion-positive thyroid cancers.

The drug will be jointly marketed in the United States and will be available within a week, Blueprint said.

Only about 1-2% of patients with NSCLC have RET fusions, according to Roche.

Reporting by Manojna Maddipatla in Bengaluru; Editing by Sandra Maler

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up